Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HK1 | P19367 | 1/20 | 0.50 |
| ▸ | HK2 | P52789 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrose SCHEMBL769631 | 1.00 | HK1 (0.50) | HK1HK2CYP1A2NFKB1THPO | |
| B-D-Galactose SCHEMBL10543506 | 1.00 | HK1 (0.50) | HK1HK2CYP1A2NFKB1THPO | |
| B-D-Galactose SCHEMBL27713886 | 1.00 | HK1 (0.50) | HK1HK2CYP1A2NFKB1THPO | |
| D-Mannose SCHEMBL28638354 | 1.00 | HK1 (0.50) | HK1HK2CYP1A2NFKB1THPO | |
| B-D-Galactose SCHEMBL8600245 | 1.00 | HK1 (0.50) | HK1HK2CYP1A2NFKB1THPO | |
| D-Galactose SCHEMBL769918 | 1.00 | HK1 (0.50) | HK1HK2CYP1A2NFKB1THPO | |
| B-D-Galactose SCHEMBL7519216 | 1.00 | HK1 (0.50) | HK1HK2CYP1A2NFKB1THPO | |
| P-Nitrophenol SCHEMBL344882 | 0.98 | HK1 (0.51) | HK1HK2CYP1A2NFKB1THPO | |
| B-D-Galactose SCHEMBL28038798 | 0.89 | CYP1A2 (0.46) | HK1HK2CYP1A2NFKB1THPO | |
| Cellobiose SCHEMBL18203876 | 0.87 | TYR (0.51) | CYP1A2NFKB1THPOALDH1A1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240167010-A9 | A GENETICALLY MODIFIED CELL LINE PRODUCING A RECOMBINANT GLYCOPROTEIN HAVING A MANNOSE-TERMINATED N-GLYCAN | WuXi Biologics Ireland Limited (IE) | 2024-05-23 | — | — | US | disclosed |
| US-20230287378-A1 | A GENETICALLY MODIFIED CELL LINE PRODUCING A RECOMBINANT GLYCOPROTEIN HAVING A MANNOSE-TERMINATED N-GLYCAN | WuXi Biologics Ireland Limited (IE) | 2023-09-14 | — | — | US | disclosed |
| EP-4139442-A1 | A GENETICALLY MODIFIED CELL LINE PRODUCING A RECOMBINANT GLYCOPROTEIN HAVING A MANNOSE-TERMINATED N-GLYCAN | Wuxi Biologics Ireland Limited (IE) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021213422-A1 | A GENETICALLY MODIFIED CELL LINE PRODUCING A RECOMBINANT GLYCOPROTEIN HAVING A MANNOSE-TERMINATED N-GLYCAN | WUXI BIOLOGICS (SHANGHAI) CO., LTD. (CN) | 2021-10-28 | — | — | WO | disclosed |
| CN-105316303-B | Beta-glucosidase I variant with improved characteristic | 丹尼斯科美国公司 | 2019-05-31 | — | — | CN | disclosed |
| CN-106222157-B | Immobilized enzyme with polyamino acid modified polystyrene resin as carrier and preparation method thereof | 南京工业大学 | 2019-02-22 | — | — | CN | disclosed |
| CN-104818262-B | A kind of method for carrying out polygonin bioconversion using heat-resisting beta-glucosidase and its mutant | 南京师范大学 | 2018-04-24 | — | — | CN | disclosed |
| CN-104818261-B | The application of a kind of heat-resisting β glucuroides and its mutant in arctigenin is prepared | 南京师范大学 | 2017-11-17 | — | — | CN | disclosed |
| CN-107217076-A | A kind of method for preparing hydroxytyrosol that enzymatic is combined with pyrohydrolysis | 南京林业大学 | 2017-09-29 | — | — | CN | disclosed |
| CN-106222157-A | Immobilized enzyme with polyamino acid modified polystyrene resin as carrier and preparation method thereof | 南京工业大学 | 2016-12-14 | — | — | CN | disclosed |
| US-20120015407-A1 | Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods | BATTELLE ENERGY ALLIANCE, LLC (US) | 2012-01-19 | — | — | US | disclosed |
| US-7858353-B2 | Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods | BATTELLE ENERGY ALLIANCE, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2235174-A1 | THERMOPHILIC AND THERMOACIDOPHILIC BIOPOLYMER- DEGRADING GENES AND ENZYMES FROM ALICYCLOBACILLUS ACIDOCALDARIUS AND RELATED ORGANISMS, METHODS | Battelle Energy Alliance, LLC (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20090203107-A1 | Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods | BATTELLE ENERGY ALLIANCE, LLC (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009099858-A1 | THERMOPHILIC AND THERMOACIDOPHILIC BIOPOLYMER- DEGRADING GENES AND ENZYMES FROM ALICYCLOBACILLUS ACIDOCALDARIUS AND RELATED ORGANISMS, METHODS | BATTELLE ENERGY ALLIANCE, LLC (US) | 2009-08-13 | — | — | WO | disclosed |
| US-7189414-B2 | Controlled release oral drug delivery system | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-03-13 | — | — | US | disclosed |
| US-20040219216-A1 | Controlled release oral drug delivery system | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-11-04 | — | — | US | disclosed |
| US-20040185107-A1 | Controlled release oral drug delivery system | RUBINSTEIN ABRAHAM (IL) | 2004-09-23 | — | — | US | disclosed |
| US-6692766-B1 | FOR INCREASING THE BIOAVAILABILITY OF ORALLY ADMINISTERED DRUGS BELONGING TO THE FOLLOWING CATEGORIES: LARGE MOLECULAR WEIGHT DRUGS, DRUGS THAT LOSE THEIR POTENCY IN THE GASTROINTESTINAL TRACT AS A RESULT OF ENZYMATIC DEGRADATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-17 | — | — | US | disclosed |
| WO-1995034294-A1 | CONTROLLED RELEASE ORAL DRUG DELIVERY SYSTEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240167010-A9 | A GENETICALLY MODIFIED CELL LINE PRODUCING A RECOMBINANT GLYCOPROTEIN HAVING A MANNOSE-TERMINATED N-GLYCAN | MGAT1, UGGT1, GALNT1 | HK1 869/4885HK2 1084/4885CYP1A2 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.